Exclusive Summary

• Targets a massive global baseline of over 40 million patients with atrial fibrillation and arrhythmias, characterized by rigid demand driven by population aging.
• The unique 50mg low-dose specification enables precise titration for sensitive populations, strategically avoiding the red-ocean competition of standard 150mg+ dosages.
• Highly recommended by AHA/ESC guidelines with no patent barriers, leveraging China's cost-effective supply chain to secure lucrative profit margins for global distributors.